306 CHAPTER 4.1 Table SI1.1. Continued. STOPP criteria (n=79) All countries Belgium (BE) Switzerland (CH) Ireland (IE) The Netherlands (NL) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) Frequency (N) Acceptance (%) E 3. Factor Xa inhibitors (e.g. rivaroxaban, apixaban) if eGFR < 15 ml/min/1.73m2 21 9.5% 0 N/A 18 5.6% 2 50.0% 1 0.0% C 10. NSAID and vitamin K antagonist, direct thrombin inhibitor or factor Xa inhibitors in combination 20 45.0% 0 N/A 15 26.7% 5 100% 0 N/A E 6. Metformin if eGFR < 30 ml/min/1.73m2 18 50.0% 3 33.3% 10 60.0% 1 0% 4 50.0% B 11. ACE inhibitors or Angiotensin Receptor Blockers in patients with hyperkalaemia. 17 35.3% 2 0% 6 33.3% 9 44.4% 0 N/A K 2. Neuroleptic drugs (in patients with risk of falls) 17 47.1% 1 100% 11 36.4% 3 66.7% 2 50.0% B 9. Loop diuretic for treatment of hypertension with concurrent urinary incontinence. 15 6.7% 0 N/A 12 0% 1 100% 2 0% H 9. Oral bisphosphonates in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding 15 0% 8 0% 0 N/A 7 0% 0 N/A D 9. Neuroleptic antipsychotic in patients with behavioural and psychological symptoms of dementia (BPSD) unless symptoms are severe and other non-pharmacological treatments have failed 14 42.9% 0 N/A 9 33.3% 4 75.0% 1 0%
RkJQdWJsaXNoZXIy MTk4NDMw